Raissa Quezado da Nobrega
Pain Medicine · Washington, DCNPI 1629500582
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,000 of the $15,816 with a category attached, or 63.2%. Medtronic accounts for 65.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $10,468 and has fallen 99.8% since, to $25 in 2025.
Across 50 payments — averaging $316.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Abbott$5K
- SPR Therapeutics, Inc$193
- Nalu Medical, Inc.$147
- Boston Scientific$122
- Saluda Medical Americas, Inc.$106
- plus $163 from 4 others
What the payments were for
- Grants$10,00063%
- Travel & lodging$2,88318%
- Food & beverage$2,93319%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $10,322 |
| Abbott | 34 | $4,763 |
| SPR Therapeutics, Inc | 2 | $193 |
| Nalu Medical, Inc. | 1 | $147 |
| Boston Scientific | 1 | $122 |
| Saluda Medical Americas, Inc. | 1 | $106 |
| Nevro Corp. | 1 | $74 |
| Stratus Medical, LLC | 1 | $44 |
| Merck | 1 | $25 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$10,000
- PROCLAIM$4,095
- SPRINT PNS System$150
- Nalu Neurostimulation System$147
- INTELLIS$128
- Infinion 16$122
- Evoke SCS$106
How this compares
Too few pain medicine providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 37 | $1,946 |
| Gabapentin | 100 | $1,750 |
| Lidocaine | 21 | $1,201 |
| Pregabalin | 49 | $812 |
| Duloxetine Hcl | 73 | $701 |
| Tizanidine Hcl | 25 | $642 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 40 | $474 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $431 |
| Oxycodone Hcl | 24 | $213 |
| Tramadol Hcl | 20 | $126 |
| Cyclobenzaprine Hcl | 13 | $82 |
| Meloxicam | 13 | $53 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Washington
- Mehul DesaiWashington$339K
- Geet PaulWashington$18K
- Sina Davari FaridWashington$9K
- Knell VillartaWashington$8K
- Brent EarlsWashington$7K
- Michael Pitts-KieferWashington$6K
- May ChinWashington$2K
- James PendletonWashington$1K
- Julia FrankWashington$1K
- Navid RashidWashington$352
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.